Search

Your search keyword '"Toussirot, Eric"' showing total 551 results

Search Constraints

Start Over You searched for: Author "Toussirot, Eric" Remove constraint Author: "Toussirot, Eric"
551 results on '"Toussirot, Eric"'

Search Results

2. Concordance and agreement between different activity scores in polymyalgia rheumatica

3. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

5. IL-17 inhibitors in axial spondyloarthritis. An overview

7. Evolution of monoclonal gammopathy of undetermined significance in patients treated with JAK inhibitors for rheumatic diseases: data from the MAJIK-SFR registry.

9. Evolution of monoclonal gammopathy of undetermined significance in patients treated with JAK inhibitors for rheumatic diseases: data from the MAJIK-SFR registry

10. ATHLETIQUE: interest of an adapted physical activity program in patients with juvenile idiopathic arthritis: a feasibility and preliminary effectiveness study

11. Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study

12. Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19 (COVIC-19): protocol for a randomised, open-label trial

13. Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19 (COVIC-19):protocol for a randomised, open-label trial

15. Advances in pharmacotherapies for axial spondyloarthritis.

17. Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study

20. Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy

23. Lack of association between the TNFAIP3 rs2230926 variant and rheumatoid arthritis-associated lymphoma

24. Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy

34. The Risk of Cardiovascular Diseases in Axial Spondyloarthritis. Current Insights

35. Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases

36. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study

42. Lymphoma complicating rheumatoid arthritis: results from a French case–control study

44. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

48. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients

49. The Interrelations between Biological and Targeted Synthetic Agents Used in Inflammatory Joint Diseases, and Obesity or Body Composition

50. Additional file 1 of Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study

Catalog

Books, media, physical & digital resources